TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21335482

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 391
Study: 19297346

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg every 4 weeks
Number of subjects: 673

Group type: COMPARATOR
Intervention: Methotrexate starting at 7.5 mg/week titrated to 20 mg/week
Number of subjects: 673

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 673
Study: 17491221

Group type: EXPERIMENTAL
Intervention: Coronary calcification (CC)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Aortic calcification
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Severity of CC and severity of aortic calcification
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Triple-vessel disease
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Age > 65 years
Number of subjects: 432
Study: 16053368

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 2.5% lidocaine gel
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 210
Study: 12052273

Group type: EXPERIMENTAL
Intervention: Early coronary angiography and percutaneous or operative revascularization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracoronary stenting and intravenous glycoprotein IIb/IIIa antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 0
Study: 10201667

Group type: EXPERIMENTAL
Intervention: 10 U/kg of unfractionated heparin
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 20 U/kg of unfractionated heparin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 75
Study: 7601403

Group type: EXPERIMENTAL
Intervention: LeVeen shunt with titanium tip
Number of subjects: 81

Group type: COMPARATOR
Intervention: Therapeutic paracentesis plus intravenous albumin
Number of subjects: 81
Study: 2118858

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) 3.75 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 378504

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 30568294

Group type: EXPERIMENTAL
Intervention: PF-05280014 plus paclitaxel
Number of subjects: 707

Group type: COMPARATOR
Intervention: trastuzumab-EU plus paclitaxel
Number of subjects: 707
Study: 28899844

Group type: EXPERIMENTAL
Intervention: Lipid ibuprofen 1200 mg/day
Number of subjects: 462

Group type: COMPARATOR
Intervention: Soft-gel ibuprofen 1200 mg/day
Number of subjects: 462

Group type: COMPARATOR
Intervention: Soft-gel ibuprofen 2400 mg/day
Number of subjects: 462
Study: 25845547

Group type: EXPERIMENTAL
Intervention: Preemptive scalp infiltration with 0.5% ropivacaine and 1% lidocaine (group A)
Number of subjects: 60
Study: 24071367

Group type: EXPERIMENTAL
Intervention: 150mg GBP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300mg GBP
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0mg GBP
Number of subjects: 0
Study: 21852703

Group type: EXPERIMENTAL
Intervention: Invitation for breast screening
Number of subjects: 60708

Group type: COMPARATOR
Intervention: No invitation for breast screening
Number of subjects: 60708
Study: 19526751

Group type: EXPERIMENTAL
Intervention: Tongmai Recipe (TMR)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cilostazol (Control)
Number of subjects: 45
Study: 17520230

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic evaluation from the perspective of statutory health insurance (SHI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-minimisation and cost-benefit analyses
Number of subjects: 0
Study: 15777382

Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Axillary clearance (AC)
Number of subjects: 622
Study: 12497721

Group type: EXPERIMENTAL
Intervention: Corticosteroids in bacterial meningitis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9706859

Group type: EXPERIMENTAL
Intervention: Test gel
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 5

Group type: COMPARATOR
Intervention: No gel
Number of subjects: 5
Study: 7659625

Group type: EXPERIMENTAL
Intervention: Asthma patient education protocol used by 28 GPs
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (18 GPs)
Number of subjects: 85
Study: 2782362

Group type: EXPERIMENTAL
Intervention: Sublingual and oral nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous and oral ritodrine
Number of subjects: 0
Study: 943354

Group type: EXPERIMENTAL
Intervention: Methandrostenolone at a dose of 25 mg im.m. per day for the first ten days from the beginning of symptoms
Number of subjects: 486

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 486
Study: 31463925

Group type: EXPERIMENTAL
Intervention: Isometric handgrip (IHG) training, 4 unilateral 2-min contractions at 30% of maximal voluntary contraction, 5 days per week for 8 weeks.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (CON) group, no intervention.
Number of subjects: 22
Study: 31060939

Group type: EXPERIMENTAL
Intervention: aPRP treatment group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 28919143

Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate 50 μg twice daily (BID)
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Tiotropium 18 μg once daily (OD)
Number of subjects: 1086
Study: 25296098

Group type: EXPERIMENTAL
Intervention: Daily PrEP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent PrEP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23812243

Group type: COMPARATOR
Intervention: Catheter angiography (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Digital subtraction angiography (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cone-beam CT (group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Procedural personnel (interventionist)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lesion delineation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Image quality estimation
Number of subjects: 40
Study: 21692285

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Chengshan (BL 57)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Medication group (Naproxen Sunstained Release Capsule, 2 tablets taken 30 min after operation and then 2 tablets a day before dressing change)
Number of subjects: 120
Study: 19889206

Group type: EXPERIMENTAL
Intervention: TachoSil patches
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard compression with surgical swabs
Number of subjects: 20
Study: 16880480

Group type: EXPERIMENTAL
Intervention: Mental healthcare intervention
Number of subjects: 204
Study: 15036064

Group type: EXPERIMENTAL
Intervention: Lorazepam (30 microg/kg)
Number of subjects: 8
Study: 11354448

Group type: EXPERIMENTAL
Intervention: 4.5 ml polylactic acid (PLA) bioabsorbable syndesmotic screw
Number of subjects: 32

Group type: COMPARATOR
Intervention: 4.5 mm stainless steel syndesmotic screw
Number of subjects: 32
Study: 9216530

Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% lidocaine infiltration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream application followed by infiltration of 1% lidocaine
Number of subjects: 0
Study: 7956864

Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 158
Study: 2445118

Group type: EXPERIMENTAL
Intervention: Mexiletine 200 mg t.i.d.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Mexiletine perlongettes 360 mg b.i.d.
Number of subjects: 21
Study: 29526693

Group type: EXPERIMENTAL
Intervention: Commercial non-carbonated LCS lemonade (330 ml) consumed with meals
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 660 ml LCS lemonade daily (habituation group)
Number of subjects: 166

Group type: COMPARATOR
Intervention: 660 ml water (control group)
Number of subjects: 166
Study: 28760204

Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 1154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1154
Study: 25658564

Group type: EXPERIMENTAL
Intervention: Systematic review by ASP IDP at day 1 and days 3 to 4
Number of subjects: 246

Group type: COMPARATOR
Intervention: No systematic review (usual care)
Number of subjects: 246
Study: 24131140

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine
Number of subjects: 861

Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 861
Study: 20623311

Group type: EXPERIMENTAL
Intervention: Joint lavage in combination with triamcinolone hexacetonide (TH) intra-articular injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Triamcinolone hexacetonide (TH) intra-articular injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Joint lavage in combination with TH
Number of subjects: 60
Study: 18926392

Group type: EXPERIMENTAL
Intervention: Patients with SCA (group 1: 95 nontransfused patients)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Patients with SCA (group 2: 12 patients on chronic transfusion therapy)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Patients with SCA
Number of subjects: 107

Group type: COMPARATOR
Intervention: Normal children and adolescents (control group)
Number of subjects: 107
Study: 16626351

Group type: EXPERIMENTAL
Intervention: Patient information leaflets
Number of subjects: 110

Group type: COMPARATOR
Intervention: Verbal consent only
Number of subjects: 110
Study: 12837672

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (250 mg/day - 1,500 mg/day; mean: 851 mg/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 46
Study: 10784625

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: AHS infection
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Age less than 10 years
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Intensively timed induction
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine intensification
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: AHS bacteremia
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: AHS bacteremia in bone marrow transplant patients
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Gastrointestinal toxicity
Number of subjects: 874
Study: 8762198

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring during a work day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ambulatory blood pressure monitoring during a non-work day
Number of subjects: 80
Study: 1405426

Group type: EXPERIMENTAL
Intervention: Methacholine inhalation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Free running exercise challenge
Number of subjects: 21
Study: 3159530

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 75 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29538185

Group type: EXPERIMENTAL
Intervention: Yoga intervention (6 weeks)
Number of subjects: 23
Study: 27430374

Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (25 mg artesunate and 55 mg mefloquine) once a day for 3 days
Number of subjects: 945

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (20 mg artemether and 120 mg lumefantrine) twice a day for 3 days
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine
Number of subjects: 945

Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 945
Study: 24509120

Group type: EXPERIMENTAL
Intervention: Married individuals
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Married men
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Married women
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Married nonblacks
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Married blacks
Number of subjects: 325
Study: 22871988

Group type: EXPERIMENTAL
Intervention: Targeted nodal assessment and ultrastaging (TNA-us)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard pathological evaluation (control)
Number of subjects: 192
Study: 20421332

Group type: EXPERIMENTAL
Intervention: 0.1 IU/kg per day rhGH
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.2 IU/kg per day rhGH
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: rhGH (both doses)
Number of subjects: 45
Study: 19077190

Group type: EXPERIMENTAL
Intervention: Exercise on Prescription program with weekly exercise sessions for 20 weeks
Number of subjects: 360

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 360
Study: 16339703

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO) adherence counseling and education
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Self-rated adherence using Numerical Likert Scale (NLS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Liver iron concentration (LIC) assessment by SQUID biosusceptometer
Number of subjects: 90
Study: 12828743

Group type: EXPERIMENTAL
Intervention: Synchronous balneo-phototherapy (simultaneous application of narrowband ultraviolet B and bathing in 10% Dead Sea salt solution)
Number of subjects: 194
Study: 10494182

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic cell transplantation (AHCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral blood as a source of transplant material
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various methods of immunotherapy (interleukin‐2, Linomid, mixed hemopoietic cell transplantation)
Number of subjects: 0
Study: 8559426

Group type: EXPERIMENTAL
Intervention: Type II diabetes patients
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Type I diabetes patients
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Regression models including age and BMI
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Regression models including height
Number of subjects: 429
Study: 2069877

Group type: EXPERIMENTAL
Intervention: Loading dose regimen of tamoxifen (160 mg for two days followed by 40 mg/day)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Conventional schedule of tamoxifen (40 mg/day)
Number of subjects: 193
Study: 7081091

Group type: EXPERIMENTAL
Intervention: Beef as the only meat for 3 months
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Poultry and fish for 3 months
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Pork for 3 months
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: All subjects combined
Number of subjects: 76
Study: 31923762

Group type: EXPERIMENTAL
Intervention: NanoTRAIL (TRAIL/Apo2L-iron oxide nanoparticles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NanoTRAIL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0

Group type: COMPARATOR
Intervention: TRAIL/Apo2L monotherapy
Number of subjects: 0
Study: 31286428

Group type: EXPERIMENTAL
Intervention: Vouchers for subsidized early childcare
Number of subjects: 0
Study: 28118280

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 25905845

Group type: EXPERIMENTAL
Intervention: Narrative film
Number of subjects: 704

Group type: COMPARATOR
Intervention: Nonnarrative film
Number of subjects: 704
Study: 23667467

Group type: EXPERIMENTAL
Intervention: Estrogen combined with medroxyprogesterone acetate therapy
Number of subjects: 38908

Group type: EXPERIMENTAL
Intervention: Estrogen therapy alone
Number of subjects: 38908
Study: 21380544

Group type: EXPERIMENTAL
Intervention: High-fat meal (HF)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isocaloric control meal (CON)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-fat meal with exercise (HFE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isocaloric control meal with exercise (CONE)
Number of subjects: 8
Study: 19894006

Group type: EXPERIMENTAL
Intervention: Functional magnetic stimulation (20-min stimulation session twice daily for 3 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Functional magnetic stimulation
Number of subjects: 16
Study: 17159079

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 26

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 26
Study: 15530138

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.15 uL/Kg
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Meperidine 1 mg/kg
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Induction morphine
Number of subjects: 1029

Group type: COMPARATOR
Intervention: No narcotic
Number of subjects: 1029
Study: 14665865

Group type: EXPERIMENTAL
Intervention: 19 intravesical instillations of epirubicin (30 mg/30 ml in normal saline) over 1 year (group 1)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 9 intravesical instillations of epirubicin (30 mg/30 ml in normal saline) over 3 months (group 2)
Number of subjects: 150
Study: 10403729

Group type: EXPERIMENTAL
Intervention: Empirical eradication therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: OGD
Number of subjects: 104
Study: 8524717

Group type: EXPERIMENTAL
Intervention: Smoking prevalence survey
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Smoking cessation program combining physician's anti-smoking message with Indian Community Health Representatives' efforts
Number of subjects: 1369
Study: 2177997

Group type: EXPERIMENTAL
Intervention: Mebeverine and high-fibre dietary advice
Number of subjects: 111

Group type: COMPARATOR
Intervention: Mebeverine plus ispaghula
Number of subjects: 111
Study: 7029236

Group type: EXPERIMENTAL
Intervention: Subunit vaccine (SV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole virus vaccine (WVV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All three vaccines
Number of subjects: 0
Study: 30671796

Group type: EXPERIMENTAL
Intervention: Pylorus-Preserving (PP)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Pylorus-Resecting (PR)
Number of subjects: 188
Study: 30335525

Group type: EXPERIMENTAL
Intervention: in vivo exposure therapy (iVET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: virtual reality exposure therapy (VRET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: augmented reality exposure therapy (ARET)
Number of subjects: 0
Study: 28665534

Group type: EXPERIMENTAL
Intervention: ICS with Indacaterol and Tiotropium (IND/TIO)
Number of subjects: 14

Group type: COMPARATOR
Intervention: ICS with Indacaterol (IND)
Number of subjects: 14
Study: 27620652

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24360745

Group type: EXPERIMENTAL
Intervention: Ditto™ intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 75
Study: 22134475

Group type: EXPERIMENTAL
Intervention: Acute dietary phenylalanine and tyrosine depletion (APTD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19752552

Group type: EXPERIMENTAL
Intervention: terutroban 10 mg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: terutroban 10 mg/day + aspirin 300 mg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: clopidogrel 75 mg/day + aspirin 300 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: aspirin 300 mg/day
Number of subjects: 48
Study: 17300633

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQP)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Mefloquine and artesunate (MAS3)
Number of subjects: 464
Study: 15134983

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg once daily plus standard care
Number of subjects: 8113

Group type: COMPARATOR
Intervention: Standard care alone (placebo)
Number of subjects: 8113
Study: 12226772

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Soft collar
Number of subjects: 8
Study: 9659322

Group type: EXPERIMENTAL
Intervention: Direct ophthalmoscope
Number of subjects: 98

Group type: COMPARATOR
Intervention: Slit lamp biomicroscope
Number of subjects: 98
Study: 7661882

Group type: EXPERIMENTAL
Intervention: Cholestyramine treatment
Number of subjects: 5

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 5
Study: 30238302

Group type: EXPERIMENTAL
Intervention: PCR‐RFLP analysis
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Rep‐PCR analysis
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Biochemical verification
Number of subjects: 59
Study: 26881996

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment manoeuvres (ARM) and surfactant administration every 8 hours for 3 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual treatment only
Number of subjects: 31
Study: 25307993

Group type: EXPERIMENTAL
Intervention: RIS
Number of subjects: 10
Study: 23316699

Group type: EXPERIMENTAL
Intervention: TAP50 (tapentadol hydrochloride extended-release 50 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TAP250 (tapentadol hydrochloride 250 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: OXY40 (OxyContin® 40 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TAP50
Number of subjects: 25

Group type: COMPARATOR
Intervention: OXY40
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TAP250
Number of subjects: 25
Study: 20200310

Group type: EXPERIMENTAL
Intervention: Insulin infusion (2 units/h with 100 ml of 5% dextrose/h for 4 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dextrose infusion (100 ml of 5% dextrose/h for 4 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion (100 ml of saline/h for 4 h)
Number of subjects: 10
Study: 17979898

Group type: EXPERIMENTAL
Intervention: Intervention group (interdisciplinary team of geriatrics specialists)
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 874

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 874